Compare Canopy Growth Corp (CGC) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Canopy Growth Corp vs McKesson Corporation — how do they compare? Canopy Growth Corp trades at $1.02 (market cap $421.10M), while McKesson Corporation trades at $893.31 (market cap $105.14B). The key difference: McKesson Corporation is far larger — about 249.7× Canopy Growth Corp's market cap, and McKesson Corporation pays a 0.42% dividend while Canopy Growth Corp pays none. Which is the better fit depends on your goals.
| CGC | MCK | |
|---|---|---|
Market Cap | $421.10M | $105.14B |
Sector | Health | Health |
52-Week High | $1.92 | $995.69 |
52-Week Low | $0.86 | $659.01 |
Enterprise Value | $378.55M | $111.67B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CGC trades at $0.95, down 1.86% in the last session, with a neutral technical signal and mixed analyst ratings (9 buy, 11 hold, 7 sell). The company reported Q1 2027 revenue growth of 13% year-over-year, beating estimates, but continues to post net losses. Recent news highlights expansion in European cannabis markets and cost-cutting efforts, while the stock remains volatile amid regulatory uncertainty.
Outlook is cautious due to persistent losses and high debt, though improving cash flow and revenue growth offer potential upside. Key risks include regulatory delays in U.S. cannabis rescheduling and competitive pressures. Investors should weigh the speculative nature against any positive regulatory catalysts.
McKesson (MCK) trades at $879.87, up 1.18% today, with strong momentum from recent earnings beats and raised guidance. The stock shows bullish technical signals, supported by robust revenue growth and solid cash flow generation. Recent news highlights strength in specialty drugs and oncology, driving positive sentiment.
Outlook remains favorable with a consensus price target of $990.67, though thin profit margins and high liabilities pose risks. Continued execution on growth initiatives and cost discipline are key for sustained upside, while macroeconomic pressures and competitive dynamics require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
